Congresses

Titlesort ascending Year
Triple oral beta-lactam containing therapy for Buruli ulcer treatment shortening 2019
Towards the elucidation of the rifampicin/beta-lactam synergy in mycobacteria 2019
Towards the elucidation of the rifampicin/beta-lactam synergy in mycobacteria 2019
TOWARDS THE ELUCIDATION OF THE MODE OF ACTION OF A NEW CHEMICAL SERIES WITH ANTIMICROBIAL ACTIVITY 2019
Towards the elucidation of rifampicin/betalactam synergistic interactions against M. tuberculosis 2018
Towards efficient in vitro screening tools to discover new clinical options in the treatment of non-tuberculous Mycobacteria 2019
The veterinary anthelmintic selamectin inhibits the mycobacterial DprE1 enzyme 2022
The D2AMR group: Discovery and development of Antimicrobials and Mechanisms of drug Resistance 2017
Study of in vitro and in vivo activity of a novel compound against Mycobacterium abscessus for the treatment of cystic fibrosis infections 2022
Strategies to elucidate the mode of action of the avermectins against mycobacteria 2021
Shortening Buruli ulcer treatment: WHO recommended <i>vs.</i> a novel betalactam containing therapy - Phase II and Phase III studies in West Africa (the BLMs4BU clinical trial) 2022
Shortening Buruli ulcer treatment: the BLMs4BU clinical trial 2022
Shortening Buruli ulcer treatment: the BLMs4BU clinical trial 2022
Shortening Buruli Ulcer treatment: the BLMS4BU clinical trial 2022
Shortening Buruli Ulcer treatment: the BLMS4BU clinical trial 2022
Sesión II: Antimicrobianos (Moderador) 2018
Sanfetrinem, repurposing an oral beta-lactam with intracellular activity for the treatment of tuberculosis 2019
Resistance to selamectin in Mycobacterium smegmatis is associated with changes in the mycobacterial envelope 2020
Repurposing clinically approved cephalosporins for tuberculosis therapy 2017
REPURPOSING BETA-LACTAMS FOR BURULI ULCER TREATMENT 2018

Pages